promiximab-duocarmycin

**Promiximab-duocarmycin** is an experimental antibody-drug conjugate (ADC) designed for the treatment of small cell lung cancer (SCLC)[1][2][3]. It is composed of *promiximab*, a novel humanized IgG1 monoclonal antibody that targets CD56 (a surface antigen highly expressed on most SCLC cells), conjugated via reduced interchain disulfides to *duocarmycin*, a highly potent DNA alkylating cytotoxin as payload[1][2][3]. The conjugate exhibits strong and specific binding to CD56, efficient internalization, and, in preclinical models, demonstrates potent antitumor activity while sparing normal tissues[1][2][3].

Other names

promiximab-DUBA